Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that regulate genes involved in energy metabolism and inflammation. For biological activity, PPARs require cognate lipid ligands, heterodimerization with retinoic X receptors, and coactivation by PPAR-g coactivator-1a or PPAR-g coactivator-1b (PGC-1a or PGC-1b, encoded by Ppargc1a and Ppargc1b, respectively). Here we show that lipolysis of cellular triglycerides by adipose triglyceride lipase (patatin-like phospholipase domain containing protein 2, encoded by Pnpla2; hereafter referred to as Atgl) generates essential mediator(s) involved in the generation of lipid ligands for PPAR activation. Atgl deficiency in mice decreases mRNA levels of PPAR-a and PPAR-d target genes. In the heart, this leads to decreased PGC-1a and PGC-1b expression and severely disrupted mitochondrial substrate oxidation and respiration; this is followed by excessive lipid accumulation, cardiac insufficiency and lethal cardiomyopathy. Reconstituting normal PPAR target gene expression by pharmacological treatment of Atgl-deficient mice with PPAR-a agonists completely reverses the mitochondrial defects, restores normal heart function and prevents premature death. These findings reveal a potential treatment for the excessive cardiac lipid accumulation and often-lethal cardiomyopathy in people with neutral lipid storage disease, a disease marked by reduced or absent ATGL activity.
of triglyceride-rich lipoproteins in tissue capillaries or de novo synthesis. Fatty acids from all these sources can activate PPARmediated gene expression 13, 14 ; however, it is currently unknown whether fatty acids require esterification to triglycerides and subsequent rehydrolysis (lipolysis) before signal transduction to the nucleus. If lipolysis is required, then the activity of ATGL and/or hormone-sensitive lipase (encoded by LIPE, referred to hereafter as HSL) 15 would be an expected step in the activation of PPARs. The relatively benign phenotype of Hsl deficiency in mice (Hsl-knockout mice, hereafter referred to as HslKO) argues against a crucial role of this enzyme in the regulation of PPARs and energy homeostasis 16, 17 . In contrast, Atgl deficiency in mice (Atgl-knockout mice, referred to hereafter as AtglKO; synonymous with Pnpla2 −/− ) is associated with reduced expression of genes responsible for oxidative phosphorylation (OXPHOS) 18 , massive lipid accumulation in multiple tissues, severe skeletal-and cardiomyopathies, and premature death 19 . Similar defects in lipid-and energy homeostasis are observed in humans with mutations in the ATGL gene 20, 21 . All affected individuals suffer from neutral lipid storage disease (NLSD) and many people develop severe skeletal myopathies, as well as cardiomyopathies that often necessitate heart transplantation 21 .
These findings inspired the hypothesis that the provision of fatty acids for PPAR activation in oxidative organs such as the heart requires ATGL-mediated lipolysis. To test this hypothesis, we assessed the expression of established PPAR-a and PPAR-d target genes in relation to mitochondrial morphology, OXPHOS and heart function in normal and mutant mice lacking either Hsl or Atgl. We show that Atgl-mediated lipolysis in cardiac muscle is essential for the biological activity of the PPAR-a-PGC-1 complex and normal heart function.
RESULTS

Atgl deficiency impairs PPAR target gene expression
Our analysis of mRNA expression in cardiac muscle of AtglKO mice revealed markedly reduced expression of PPAR-a and PPAR-d target genes, including acyl-CoA oxidase (Acox1, −72%), medium-chain acyl-CoA dehydrogenase (Acadm, −64%), long-chain acyl-CoA dehydrogenase (Acadl, −67%), very long-chain acyl-CoA dehydrogenase (Acadvl, −77%), carnitine palmitoyltransferase 1b (Cpt1b, −75%) and pyruvate dehydrogenase kinase 4 (Pdhk4, −79%) compared to the levels found in wild-type mice (Fig. 1a) . Reduction in the expression of these genes in HslKO mice was less pronounced (Acadm, −42%; Acadvl, −26%; Cpt1b, −44%) or nonexistent (Acox1, Acadl, Pdhk4). Our analysis of liver samples showed a similar mRNA expression profile characterized by marked reduction of the expression of all PPAR-a and PPAR-d target genes examined (−50% to −90%) in AtglKO mice compared to wild-type mice (Fig. 1b) , whereas only gene expression of liver-specific fatty acid-binding protein (L-Fabp, encoded by Fabp1) expression was reduced in HslKO mice (−58%). We found that measurements of PPAR proteins in AtglKO mice showed reduced concentrations of PPAR-a in the heart (−37%) and liver (−33%) (Supplementary Fig. 1a) , and of PPAR-d in the heart (−19%) compared with wild-type mice (Supplementary Fig. 1b) . As the main regulatory step for efficient transactivation of gene transcription involves the heterodimerization of PPAR proteins with RXR-a in a ligand-dependent manner, the moderate reduction in PPAR protein concentrations is unlikely to mediate the drastic decrease of PPAR target gene expression in Atgl-deficient cardiac muscle or liver. Notably, we found that PGC-1a (−80%) and PGC-1b (−85%) mRNA levels were also drastically decreased in cardiac muscle of AtglKO mice compared to wild-type mice (Fig. 1c) . This decrease was specific to cardiac muscle because mRNA levels of PGC-1a and PGC-1b were higher in the liver of AtglKO mice than in wild-type mice (Fig. 1d) , thus arguing for a tissue-specific difference in the regulation of PGC-1 expression. In cardiac muscle, we found that Atgl-deficient mice had normal PGC-1a and PGC-1b mRNA levels at birth ( Supplementary  Fig. 1c ). At weaning (14 ± 1 d after birth), however, we found that the concentration of PGC-1a mRNA decreased relative to wild-type mice by 64%, and that PGC-1b tended to decrease (−18%). This decrease in mRNA levels in both types of PGC-1 typically precedes pronounced cardiac lipid accumulation and defective heart function.
Impaired cardiac mitochondrial respiration in AtglKO mice
We carried out biochemical analyses that confirmed the previously observed increased cardiac triglyceride content in AtglKO mice (20-fold; ref. 19 ) and additionally found increased glycogen concentrations (+70%) in cardiac muscle of the mutant mice compared with wild-type mice (Fig. 2a) . Our histomorphological analysis showed that these increases were a result of increased size and number of lipid droplets and glycogen granules within cardiomyocytes (Fig. 2b) . Furthermore, although the overall morphology of mitochondria and the structure of mitochondrial cristae appeared normal in electron microscopical analyses of AtglKO cardiac muscle, mitochondrial size compared to that of wild-type mice was increased when we applied higher-resolution morphometric (+18%) and cytofluorimetric (+45%) analyses (Fig. 2c,d) . Concomitantly, we found that mitochondrial DNA content in cardiac muscle was 32% lower in AtglKO mice than in wild-type mice, thus indicating a decreased number of mitochondria in the hearts of AtglKO mice (Fig. 2e) . Figure 1 Expression of PPAR-a and PPAR-d target genes and PGC-1a and PGC-1b in AtglKO, HslKO, and wild-type tissues. mRNA expression levels for selected PPAR-a and PPAR-d target genes and PGC-1a and PGC-1b were determined by RT-qPCR analysis. (a,b) Cardiac (a) and hepatic (b) mRNA expression of PPAR-a and PPAR-d target genes were markedly decreased in fasted 8-to 10-week-old female AtglKO mice compared to age-matched HslKO and wild-type mice. (c,d) mRNA levels of genes encoding PGC-1a and PGC-1b mRNA were also reduced in cardiac muscle (c) but increased in the liver (d) of fasted AtglKO mice compared to wild-type mice. n = 4. Error bars show means ± s.d. *P < 0.05, **P < 0.01 and ***P < 0.001.
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We also found that Atgl deficiency prompted severe impairment of cardiac mitochondrial function. We prepared heart homogenates from 4-week-old ( Fig. 3a) and 8-week-old (Fig. 3b ) AtglKO mice and found drastically reduced oxygen consumption under both basal and succinatestimulated conditions. We also found that reduced oxygen consumption was irrespective of the presence of glucose (Fig. 3a,b) or palmitate ( Supplementary Fig. 2a ), thereby suggesting that the substrate energy source did not affect the mitochondrial defect. Cyanide (1 mM) stopped both basal and succinate-stimulated cardiac respiration, excluding nonmitochondrial mechanisms of oxygen consumption (data not shown). We showed that the reduction of mitochondrial oxygen consumption was similar in 4-week-old and 8-week-old AtglKO mice (between −63% and −74%) and did not correlate with cardiac triglyceride content (Fig. 3c) , which was 4.6-fold higher in older than in younger AtglKO mice.
Our analysis of respiration in isolated cardiac mitochondria revealed a markedly decreased oxygen flux specifically to the metabolically more flexible subsarcolemmal mitochondria 22, 23 (Fig. 3d,e) . We found that both ADP-driven (state 3) and uncoupled (state U) oxygen flow was decreased in AtglKO subsarcolemmal mitochondria in the presence of pyruvate (−49% and −43%, respectively) and palmitoyl-CoA (−79% and −78%, respectively). The decrease in oxygen flux in the presence of both glycolytic and lipolytic substrates associated with marked derangements in the mitochondrial respiratory chain (Fig. 3f) . Furthermore, protein quantities for NDUFA9 (complex I; NADH dehydrogenase [ubiquinone] 1a subcomplex subunit 9) and SDHA (complex II; succinate dehydrogenase complex subunit A) were 75% and 29% lower, respectively, in AtglKO mitochondria than in wild-type mitochondria (Fig. 3f) . In contrast, MTCO1 (complex IV; mitochondrial cytochrome c oxidase 1) protein quantity remained unchanged (Fig. 3f) . We showed that significantly reduced mitochondrial membrane potential (−41%) (Fig. 3g) , reduction of nonesterified free thiol groups (−51%) (Fig. 3h) and decreased fatty acid oxidation rates (Supplementary Fig. 2b ) added to the mitochondrial dysfunction in AtglKO cardiomyocytes. Thus, we suggest that reduced PPAR target gene and PGC-1a and PGC-1b expression in response to Atgl deficiency leads to defective OXPHOS in the hearts of AtglKO mice. This reduced oxidative capacity may contribute to decreased substrate utilization and increased cardiac deposition of neutral lipids and glycogen in the cardiomyocytes of AtglKO mice.
PPAR activation and OXPHOS depend on cardiac-specific ATGL To examine whether the observed defects in PPAR signaling and substrate oxidation are specific to the absence of cardiac Atgl, we pursued two strategies. First, we analyzed conditional knockout mice lacking Atgl only in muscle by generating a mouse line with a loxP-flanked Atgl gene (referred to hereafter as AtglFLOX mice) and breeding it with transgenic mice expressing the Cre recombinase under the control of the muscle-specific creatine kinase promoter. Muscle-specific recombination generated mice, referred to hereafter as muscleAtglKO mice, with extremely low Atgl mRNA levels in cardiac (−95% compared to wild-type mice) ( Supplementary  Fig. 3a ) and skeletal muscle (data not shown). We found that Atgl mRNA levels in other tissues (for example, liver) were comparable to those in wild-type mice (data not shown). Muscle-specific Atgl deletion increased heart weight 1.5-fold (127 ± 5 mg for muscleAtglKO mice versus 84 ± 12 mg for controls, P < 0.001, n = 7) and cardiac triglyceride content 10.7-fold (Fig. 4a) . mRNA expression for PPAR-a and PPAR-d target genes in cardiac muscle of muscleAtglKO mice decreased by 50-80%, and PGC-1a mRNA levels decreased by 85% (Fig. 4b) . This cardiac phenotype of muscleAtg1KO mice is indistinguishable from the one observed in conventional AtglKO mice, and it suggests a specific role for cardiac Atgl in PPAR-regulated energy metabolism. Expectedly, and in contrast to AtglKO mice, we found that muscleAtglKO mice had normal hepatic mRNA levels for the PPAR-a and PPAR-d target genes we studied ( Supplementary Fig. 3b ).
Our second strategy tested whether Atgl in the heart alone is sufficient to rescue the cardiac phenotype of AtglKO mice by generating transgenic mice with cardiomyocyte-specific overexpression of Atgl (hereafter referred to as cmAtglTG mice) (Supplementary Fig. 4a ). We subsequently backcrossed cmAtglTG mice onto an AtglKO background, yielding mice with Atgl present exclusively in cardiac muscle (designated AtglKO-cmAtglTG mice). We found that Atgl enzyme activity in cardiac muscle of AtglKO-cmAtglTG mice was five-to sevenfold higher than in wild-type mice ( Supplementary  Fig. 4b ). Cardiac-exclusive Atgl expression entirely rescued the lethal heart phenotype of conventional AtglKO mice and prolonged life span to periods comparable to those in wild-type mice (>2 years) ( Supplementary Fig. 4c ). Cardiac hypertrophy and massive triglyceride accumulation, characteristics of the Atgl-deficient heart, reverted to normal in AtglKO-cmAtglTG mice (Fig. 4c,d ), whereas adipose tissue mass remained high (Fig. 4e) . Restoration of Atgl enzyme activities in cardiac muscle caused a substantial increase in PPAR-a and PPAR-d target gene and PGC-1a and PGC-1b mRNA expression (Fig. 4f) , and it increased oxidative capacity to values found in wildtype mice (Fig. 4g) . Together, these results assign a crucial and specific role to cardiac Atgl in the activation of PPAR target gene expression and lipid oxidation. To determine whether these parameters could be attributed to differences in availability of extracellular lipid substrates, we measured plasma concentrations of lipid substrates (fatty acids and triglycerides) and cardiac LPL enzyme activities in all mouse models and correlated these with PPAR target gene expression and cardiac phenotype. We found that fasted AtglFLOX and conditional muscleAtglKO mice showed normal plasma fatty acid, triglyceride and total cholesterol concentrations, similar to those observed in fasted wild-type mice (Supplementary Table 1 ). In contrast, plasma fatty acid and triglyceride concentrations were much lower in fasted AtglKO (−67% and −66%, respectively) and AtglKO-cmAtglTG mice (−74% and −69%, respectively) than in wild-type mice. Cardiac-specific LPL enzyme activities varied among different genotypes, with the highest values observed in AtglKO and AtglKO-cmAtglTG mice (Supplementary Fig. 5a ). In AtglKO mouse hearts, this led to a 53% increase in the total intracellular concentration of unesterified fatty acids (Supplementary Fig. 5b ). In summary, these results indicate that both plasma lipid concentrations and cardiac LPL activities did not correlate with PPAR target gene expression or the severity of the cardiac phenotype.
To test whether overexpression of Atgl in an in vitro cell culture system enhances PPAR-a target gene expression, we performed reporter gene transactivation assays. We co-transfected HepG2 cells with a plasmid expressing a luciferase reporter gene under the control of multiple PPAR-responsive elements (PPREs) and an expression vector for PPAR-a. This co-transfection strongly induced luciferase reporter expression compared to cells transfected with only the PPRE-luciferase vector (Fig. 4h) . On addition of exogenous linoleic acid (18:2), we found that reporter activity increased further (by 38%) (Fig. 4h) , confirming previous reports that fatty acids induce PPAR-a target gene expression 24 . We found that additional overexpression of Atgl via an Atgl expression plasmid further augmented luciferase activity in the presence or absence of exogenous fatty acids (44% and 61%, respectively) (Fig. 4h) . Thus, we suggest that the overexpression of Atgl stimulates PPAR-a-mediated reporter gene transcription in vitro.
PPAR-a agonist restores cardiac respiration and function Next, we assessed whether the severe lipid and respiratory defects in Atgl-deficient mice can be bypassed by lipolysis-independent PPAR activation via PPAR agonists. We found that feeding 6-week-old female AtglKO mice a chow diet containing 0.1% (wt/wt) of the PPAR-a agonist Wy14643 for 3 weeks decreased circulating triglycerides and fatty acids (Supplementary Table 2 ) and substantially reduced triglyceride content in heart (−52%) and liver (−50%) compared to AtglKO mice fed a normal chow diet (Fig. 5a) . Similarly, feeding AtglKO mice a chow diet containing 0.2% (wt/wt) of the alternative PPAR-a agonist fenofibrate for 10 weeks reduced the cardiac and hepatic triglyceride contents by 62% and 49%, respectively (Fig. 5b) . In addition, we found that Wy14643 treatment caused a substantial increase in PPAR-a target gene expression (Fig. 5c) . Notably, we found that PGC-1a and b mRNA levels also reverted to wild-type values after Wy14643 treatment (Fig. 5c) . Agonist treatment also improved basal and succinate-stimulated respiratory rates of AtglKO hearts to wild-type values (Fig. 5d) , normalized free thiol concentrations (Supplementary Fig. 6a ), and partially Fig. 6b ) and membrane potential (Supplementary Fig. 6c ). We found that the beneficial effects of Wy14643 were not caused by an induction of cardiac triglyceride hydrolase activity (Supplementary Fig. 6d ). PPAR-a agonist treatment substantially improved heart function in AtglKO mice. In echocardiography (Fig. 5e and Supplementary  Table 3) , AtglKO mice showed a massive increase in left ventricular mass index. This was largely the result of a thickening of the septal and posterior walls (without substantial change in the left ventricular end-diastolic dimension), thus resulting in a concentric hypertrophic phenotype ( Fig. 5e and Supplementary Table 3) . Left ventricular systolic function was significantly impaired in AtglKO mice, as indicated by an increase in left ventricular end-systolic dimensions and a robust decrease in left ventricular fractional shortening (Fig. 5e  and Supplementary Table 3) . A 3-week treatment with the PPAR-a agonist Wy14643 completely reversed this phenotype (Fig. 5e and  Supplementary Table 3) . We showed that treated AtglKO mice had normal ventricular systolic function and a left ventricular mass index comparable to wild-type animals (Fig. 5f,g ). In fact, left ventricular end-diastolic dimensions of treated AtglKO mice were even lower than in wild-type mice (Supplementary Table 3) . Thus, we suggest that exogenous PPAR-a stimulation is sufficient to markedly improve mitochondrial function and to fully restore the cardiac performance of AtglKO mice.
Wy14643 prevents cardiac death and improves fatty acid utilization
To investigate whether PPAR-a agonist-mediated improvement of respiratory function and cardiac performance prevents the early death of AtglKO mice, we kept 8-week-old AtglKO males on a chow diet with and without Wy14643 for 12 weeks. Although all vehicle-treated knockout mice died within the first 4 weeks of the treatment period, 4 out of 5 Wy14643-treated knockout mice survived the complete duration of the experiment (Fig. 6a) . One animal of the Wy14643 group was bitten to death during the second week of treatment. Notably, we found that on this long-term treatment regimen with the PPAR-a agonist, cardiac muscle and liver triglyceride content in AtglKO mice was equivalent to that seen in wild-type mice (Fig. 6b) . Triglyceride content also was low in other Atgl-deficient organs including kidney, testis and ileum (Fig. 6b) .
At the same time, the physical performance of AtglKO mice and their 'metabolic flexibility' in terms of energy substrate utilization improved after a 7-d treatment with Wy14643. We found that during the dark cycle when the mice are more active, oxygen consumption in metabolic chambers was 12% lower in AtglKO mice than in wild-type mice (Fig. 6c) . This difference decreased to 9% when the mice received Wy14643. To test for metabolic flexibility, we assessed mice fed a chow diet with or without Wy14643 by indirect calorimetry (Fig. 6d) . During the dark period (when mice eat), we found that values for the respiratory quotient were ~1.0, suggesting that glucose was the only energy substrate used in both genotypes (Fig. 6d) . During the light period (when mice typically decrease their food intake) or during food deprivation 3 h before the experiment, the respiratory quotient values of wild-type animals dropped to 0.89 and 0.80, respectively, indicating a switch from glucose to fatty acid utilization (Fig. 6d) . These decreases were less pronounced in AtglKO mice (0.92 in animals during the light cycle and 0.83 after fasting), suggesting that the animals were less efficient in switching the energy substrate from glucose to fatty acids (Fig. 6d) . In addition, we found that Wy14643 administration significantly decreased the respiratory quotient values in both wild-type and AtglKO mice (Fig. 6d) . However, respiratory quotients remained higher in AtglKO mice than in wild-type mice (Fig. 6d) . Thus, we suggest that PPAR agonist treatment increases fatty acid utilization in both genotypes but is unable to fully restore fatty acid oxidation in AtglKO mice to wild-type values. Presumably, this results from the restricted fatty acid availability in fasted AtglKO mice due to lipolytic defects in white adipose tissue.
PPAR-d agonists do not improve the cardiometabolic defects
In addition to PPAR-a, PPAR-d has a prominent role in the transcriptional regulation of genes involved in fatty acid uptake and oxidation in many tissues, including cardiac and skeletal muscle [25] [26] [27] .
To differentiate between PPAR-a-and PPAR-d-mediated effects, we investigated whether the administration of the well-established selective PPAR-d agonists GW501516 (ref. 27 ) and GW0742 (ref. 28) can also improve the cardiometabolic defects in AtglKO mice. Consistent with previous observations 27 , we found that daily intraperitoneal administration of GW501516 at 5 µg per g body weight to 7-week-old mice for 2 weeks decreased hepatic triglyceride content in wild-type and AtglKO mice (−37% and −29%, P < 0.08, respectively) (Supplementary Fig. 7a) and increased the expression of PPAR-a and PPAR-d target genes to wild-type values (Supplementary Fig. 7b) . Unexpectedly, however, we found that PPAR-d agonist treatment did not improve the cardiac phenotype of AtglKO mice (Supplementary Fig. 7c-e) . GW501516 increased rather than decreased the cardiac triglyceride content ( Supplementary  Fig. 7c ) in both wild-type (2.2-fold) and AtglKO mice (1.3-fold). PPAR target gene expression (Supplementary Fig. 7d ) and cardiac oxygen consumption (Supplementary Fig. 7e ) remained unaffected. We found that application of GW501516 by oral gavage (5 µg per g body weight) twice a day for 4 d yielded similar results ( Supplementary  Fig. 7f-h ). Whereas we found that hepatic mRNA levels for PPARd targets in AtglKO mice increased to normal ( Supplementary  Fig. 7f ), cardiac PPAR-d target gene expression ( Supplementary  Fig. 7g ) and triglyceride content (Supplementary Fig. 7h ) remained abnormal. We also found that cardiac PGC-1a and PGC-1b mRNA concentrations slightly increased in wild-type and AtglKO mice in response to GW501516; however, in treated AtglKO mice they remained 60% below those observed in untreated wild-type mice ( Supplementary  Fig. 7i ). In contrast, hepatic PGC-1a and PGC-1b mRNA levels were consistently higher in AtglKO than in wild-type mice independently of PPAR-d agonist treatment (Fig. 1d and Supplementary Fig. 7j ). In addition, oral administration of the alternative PPAR-d agonist GW0742 also had no effect on cardiac PPAR target gene expression, tissue triglyceride content, plasma lipid parameters or body weight (data not shown). 
DISCUSSION
This study shows that the activation of cardiac and hepatic gene transcription by the PPAR-a-PGC-1 complex depends on the lipolytic catabolism of cellular triglyceride depots. This process requires the hydrolytic activity of Atgl. The absence of this enzyme in cardiac muscle of conventional AtglKO mice causes a lipolytic defect that results in massive lipid accumulation, drastic reduction of PPAR-a-regulated gene expression, defective mitochondrial substrate oxidation, severe cardiac dysfunction and premature death. A similar phenotype is observed in conditional knockout mice lacking Atgl only in cardiac and skeletal muscle (muscleAtglKO), indicating that the defects are specific to the absence of Atgl in cardiomyocytes. Concurrent analysis of the liver of AtglKO mice confirmed previous observations that showed that Atgl regulates triglyceride turnover and the expression of PPAR-a target genes [29] [30] [31] . In humans, ATGL deficiency provokes a similar clinical phenotype; affected individuals develop NLSD with severe cardiomyopathy that requires cardiac transplantation in a subgroup of patients. The pronounced phenotype with respect to energy homeostasis and cardiac function is specific for Atgl deficiency because Hsl or other potential lipid hydrolases cannot compensate for the absence of this enzyme, and also because all metabolic and functional derangements in the heart can be corrected by the cardiacspecific expression of an Atgl transgene in mice that lack Atgl in all other tissues. Thus, the Atgl-mediated generation of lipolytic products is an indispensable requirement for the regulation of PPAR-a target genes and represents a previously undescribed mechanism for gene regulation. It supports the concept that lipid droplets are not only cellular compartments for energy storage but also serve as reservoirs for specific lipid mediators, which require lipolysis for their spatiotemporally coordinated release and subsequent action. Fatty acids as potential ligands for PPAR-a activity originate from two major sources. Endogenously synthesized fatty acids (that is, 'new fat') 14 predominantly regulate hepatic PPAR-a activity. In contrast, exogenous fatty acids (that is, 'old fat') 32 derived from adipose tissue (fatty acid-albumin complexes) or from the hydrolysis of hepatic very-low-density lipoprotein particles via LPL regulate cardiac PPAR-a activity. Changes in liver-specific fatty acid synthase or cardiac-specific LPL activities in mutant mouse models strongly affect energy substrate usage, PPAR signaling and cellular lipid homeostasis 14, [32] [33] [34] , proving the crucial role of these enzymes in the delivery of PPAR ligands. Our data add an additional aspect to these findings: functional PPAR signaling requires Atgl-catalyzed hydrolysis of intracellular triglyceride stores generated from endogenous or exogenous fatty acids. Apparently, fatty acids must first be esterified to triglycerides and rehydrolyzed by Atgl before they become active signaling lipids. Ligand delivery via LPL and fatty acid uptake is indispensable but by itself not sufficient for normal PPAR signaling and cardiometabolic function. Consistent with this conclusion, conventional AtglKO mice (with decreased plasma fatty acid and increased cardiac LPL activity) and conditional muscle Atgl KO mice (with normal plasma fatty acid and decreased cardiac LPL activity) showed impaired PPAR target gene expression and lethal cardiomyopathy, whereas AtglKO-cmAtglTG mice (with decreased plasma fatty acid and increased cardiac LPL activity) showed improved target gene expression and no apparent cardiomyopathy. Whether enhanced ligand delivery to the heart by the tissue-specific overexpression of LPL 33 or the fatty acid transporter CD36 (ref. 35) can overcome the cardiometabolic phenotype associated with Atgl deficiency remains to be assessed.
Our current concept can be summarized as follows: exogenous fatty acids from hydrolyzed fatty acid-albumin complexes or triglyceriderich lipoproteins enter the cell and are coenzyme-A activated by cell membrane-bound acyl-CoA synthetases and/or fatty acid transport proteins (Fig. 6e) . Depending on energy demand, these fatty acidCoAs either enter mitochondria for oxidation or are re-esterified and stored in lipid droplet triglycerides. The generation of lipolytic products such as fatty acids or diglycerides by Atgl provides ligands or ligand precursors for functional signaling by the PPAR-a-PGC-1 complex, which, in turn, activates mitochondrial biogenesis and OXPHOS and directs fatty acid-CoAs to oxidation. Conversely, downregulation or absence of Atgl leads to decreased mitochondrial biogenesis and function and directs fatty acid-CoAs toward triglyceride synthesis and accumulation.
This study did not address the molecular nature of mediators that regulate the PPAR-a-PGC-1 complex after lipolysis. Accordingly, any considerations of why lipolysis is required for the production of these mediators remain speculative. The molecular identity of PPAR ligands and the mechanisms of their transduction from the cytoplasma to the nucleus are still a matter of intense debate. A widely accepted model involves the binding of mono-and polyunsaturated fatty acids to cytoplasmic fatty acid-binding proteins (FABPs), translocation into the nucleus and binding to PPAR-RXR heterodimers, thereby accomplishing transcriptional activation 24, 36 . Alternatively, it has been proposed that fatty acid or diglyceride derivatives such as prostaglandins J2 (refs. 9,11) or 1-palmitoyl-2-oleyl-sn-glycerol-3-phosphocholine 12 , respectively, act as PPAR ligands. Atgl-mediated hydrolysis of triglycerides is compatible with both mechanisms because it generates unesterified fatty acids and diglyceride as potential lipid ligands or ligand precursors. Finally, it is even conceivable that components of lipid droplets, such as lipid droplet-associated proteins, dissociate during lipolysis and regulate PPAR signaling.
Atgl deficiency results in decreased expression of PGC-1a and PGC1b in cardiac muscle. Consistent with the established roles of PGC-1a and PGC-1b in cardiac mitochondrial biogenesis, substrate oxidation and prevention of oxidative stress 35, 37 , low cardiac PGC-1 concentrations may contribute to decreased numbers of mitochondria, decreased amounts of respiratory complex I and II proteins, accumulation of reactive oxygen species and impaired OXPHOS in cardiac muscle of AtglKO mice. Decreased mitochondrial oxygen consumption was specific to subsarcolemmal mitochondria, which are highly sensitive to cellular PGC-1a concentrations 22, 23, 38 .
The molecular mechanism whereby defective lipolysis suppresses cardiac PGC-1a and PGC-1b expression is currently unknown. Multiple physiological stimuli, including fatty acids, regulate PGC-1a expression and activity via numerous signaling pathways and posttranslational modifications 7, [39] [40] [41] . A plausible mechanism suggests a direct regulation of PGC-1a by lipolysis-dependent PPAR-a activation. A previous study 42 characterized a functional PPRE within the PGC-1a promoter that is regulated by PPAR-a agonists, whereas another 43 showed that the upregulation of mitochondrial biogenesis and function in a mouse model with insulin resistance depends on the PPAR-a-mediated upregulation of PGC-1a. Our data are consistent with these observations and suggest that lipolysis regulates PGC-1a via PPAR-a signaling. Therefore, the cardiac phenotype we found in AtglKO was more severe than in mouse lines with individual deficiencies for PGC-1a or PGC-1b, but less severe than that observed in a mouse model with combined PGC-1a and PGC-1b deficiencies 7, 44 . The latter animals die within 24 h after birth from cardiac mitochondrial dysfunction and heart failure 44 . Whether alternative mechanisms involving additional nuclear receptors (for example, the estrogen-related receptor or the retinoid-related orphan receptors) or non-nuclear receptors, such as the nuclear respiratory factors, also contribute to decreased cardiac PGC-1 expression requires clarification. Notably, our finding that PGC-1a and PGC-1b expression in the liver of AtglKO mice was higher than in wild-type mice despite decreased PPAR-a and PPAR-d target gene expression suggests basic tissue-specific differences in the regulation of PGC-1 expression in the heart and the liver that remain to be elucidated.
Treatment of AtglKO mice with PPAR-a agonists bypassed the lipolytic defect and prevented the adverse metabolic alterations and oxidative dysfunction in the heart. Wy14643 treatment of mice was previously shown to stimulate PPAR-a-activated gene expression and mitochondrial oxidation, thereby reducing cellular triglyceride content in cardiac muscle and liver [45] [46] [47] . In AtglKO mice, Wy14643 treatment restored the cardiac expression of PPAR-a target genes and PGC-1a and PGC-1b, reversed excessive systemic lipid accumulation, normalized oxidative function and oxidative stress in mitochondria, improved cardiac performance and prevented lethal cardiomyopathy. The normalization of cardiac steatosis in response to the PPAR-a agonist occurred without increasing cellular triglyceride hydrolysis, thus arguing against an induction of alternative lipase(s). The reduction in triglyceride content may be mostly secondary to increased oxidation of exogenous fatty acids and altered kinetics of the intramyocellular triglyceride pool.
In contrast, we show that PPAR-d agonist treatment of AtglKO mice via intraperitoneal injection or oral gavage neither reduces cardiac lipid content nor normalized PGC-1a and PGC-1b and PPAR target gene expression. This was unexpected as PPAR-d activation is associated with increased fatty acid oxidation in muscle and liver 27, 48 . PPAR-d agonist effects on cardiac triglyceride content have not been reported, but mice lacking PPAR-d suffer from mild cardiac steatosis (normal cardiac triglycerides in 2-month-old mice and a twofold increase when they are 9 months old) and decreased OXPHOS in cardiac muscle 25 . Our results indicate that defective PPAR-a activation and decreased PGC-1a and PGC-1b expression account for most of the cardiometabolic derangements observed in Atgl-deficient mice and that PPAR-d activation alone is not sufficient to overcome these defects in AtglKO mice. In the liver, administration of PPAR-d agonists normalized PPAR target gene expression. The agonist-mediated induction of target mRNAs was independent of PGC-1a and PGC-1b expression, which was consistently higher in the liver of AtglKO mice than in wild-type mice. These findings suggest remarkable tissue-specific differences in cardiac muscle and liver with respect to the regulation of the PPAR-PGC-1 complex by lipolysis.
The possibility that the pharmacological activation of PPAR-a can bypass the ATGL pathway offers a potential treatment for people with NLSD. Two distinct genetic defects are known to cause NLSD 49 : Mutations in ATGL cause NLSD with myopathy (NLSDM), whereas mutations in the ATGL activator CGI-58 cause NLSD with ichthyosis (NLSDI). Both conditions cause ectopic systemic lipid storage, although not to the same extent 50 . People with NLSDM accumulate large amounts of triglycerides, particularly in cardiac and skeletal muscle, and they develop only mild hepatosteatosis. People with NLSDI suffer from more severe hepatosteatosis and accrue fewer triglycerides in muscle. If our results in AtglKO mice also apply to humans, treatment with PPAR-a agonists should reduce ectopic lipid accumulation and improve organ dysfunction in these individuals. Fenofibrate, an approved and well-established activator of PPAR-a (ref. 51) , may be particularly beneficial for the treatment of liver steatosis in NLSDI. Currently, there is no clinical evidence that PPAR-a agonists also affect cardiac lipid metabolism and heart function in humans (unlike in the mouse 52 ). Instead, human skeletal muscle and cardiac energy metabolism may rely more on the activity of PPAR-d (refs. 3,53) . Accordingly, administration of recently available PPAR-d or nonselective PPAR agonists may be an effective measure to combat excessive skeletal and cardiac lipid deposition and heart failure in people with NLSDM.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
